These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 26845926)

  • 21. Letter: does the IFNL4 gene discovery really provide a causal role for the IL28B haplotype blocks?
    Galmozzi E; Lampertico P
    Aliment Pharmacol Ther; 2014 Mar; 39(5):548-9. PubMed ID: 24494849
    [No Abstract]   [Full Text] [Related]  

  • 22. KIR3DL1-HLA-Bw4 combination and IL28B polymorphism predict response to Peg-IFN and ribavirin with and without telaprevir in chronic hepatitis C.
    Umemura T; Ota M; Katsuyama Y; Wada S; Mori H; Maruyama A; Shibata S; Nozawa Y; Kimura T; Morita S; Joshita S; Komatsu M; Matsumoto A; Kamijo A; Kobayashi M; Takamatsu M; Yoshizawa K; Kiyosawa K; Tanaka E
    Hum Immunol; 2014 Aug; 75(8):822-6. PubMed ID: 24929144
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Relation of IL28B gene polymorphism to chronic hepatitis C].
    Matsuura K; Tanaka Y
    Nihon Rinsho; 2011 May; 69 Suppl 4():227-33. PubMed ID: 22096924
    [No Abstract]   [Full Text] [Related]  

  • 24. Value of interleukin-28B genetic polymorphism on retreatment outcomes of chronic hepatitis C genotype 1 relapsers by peginterferon alfa plus ribavirin.
    Chen MY; Liu CH; Chen TC; Su TH; Chen PJ; Chen DS; Kao JH; Liu CJ
    J Gastroenterol Hepatol; 2014 Jan; 29(1):102-9. PubMed ID: 23829453
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy.
    Aziz H; Raza A; Ali K; Khattak JZ; Irfan J; Gill ML
    Int J Infect Dis; 2015 Jan; 30():91-7. PubMed ID: 25462177
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Letter: does the IFNL4 gene discovery really provide a causal role for the IL28B haplotype blocks? Authors' reply.
    Stättermayer AF; Ferenci P
    Aliment Pharmacol Ther; 2014 Mar; 39(5):549-50. PubMed ID: 24494850
    [No Abstract]   [Full Text] [Related]  

  • 27. IL28B: A new wager in the skyline of hepatitis C virus infection.
    Mangia A
    Dig Liver Dis; 2011 Mar; 43(3):177-9. PubMed ID: 21237729
    [No Abstract]   [Full Text] [Related]  

  • 28. [Genetic variation of IL-28B is associated with treatment response of patients with chronic hepatitis C].
    Xie JQ; Zhang XH; Li XH; Xie DY; Xu QH
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2012 Aug; 26(4):298-300. PubMed ID: 23189850
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy.
    Hayes CN; Kobayashi M; Akuta N; Suzuki F; Kumada H; Abe H; Miki D; Imamura M; Ochi H; Kamatani N; Nakamura Y; Chayama K
    Gut; 2011 Feb; 60(2):261-7. PubMed ID: 21068134
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interleukin 28B genetic polymorphisms play a minor role in identifying optimal treatment duration in HCV genotype 1 slow responders to pegylated interferon plus ribavirin.
    Liu CH; Liang CC; Liu CJ; Tseng TC; Lin CL; Yang SS; Su TH; Lin JW; Chen JH; Chen PJ; Chen DS; Kao JH
    Antivir Ther; 2012; 17(6):1059-67. PubMed ID: 22898703
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic variants of interferon-stimulated genes and IL-28B as host prognostic factors of response to combination treatment for chronic hepatitis C.
    Lopez-Rodriguez R; Trapero-Marugan M; Borque MJ; Roman M; Hernandez-Bartolome A; Rodriguez-Muñoz Y; Martin-Vilchez S; Abad-Santos F; Muñoz de Rueda P; Vidal-Castiñeira JR; Rodrigo L; Salmeron J; Moreno-Otero R; Sanz-Cameno P
    Clin Pharmacol Ther; 2011 Nov; 90(5):712-21. PubMed ID: 21993426
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interferons and hepatitis C virus.
    Heim MH
    Swiss Med Wkly; 2012; 142():w13586. PubMed ID: 22573217
    [TBL] [Abstract][Full Text] [Related]  

  • 33. IP-10 in chronic hepatitis C patients treated with high-dose interferon.
    Willemse SB; Reesink HW; Ladee K; Karlas J; Gelderblom HC; Molenkamp R; Schinkel J
    Neth J Med; 2014 Oct; 72(8):407-15. PubMed ID: 25387553
    [TBL] [Abstract][Full Text] [Related]  

  • 34. IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B.
    Lampertico P; Viganò M; Cheroni C; Facchetti F; Invernizzi F; Valveri V; Soffredini R; Abrignani S; De Francesco R; Colombo M
    Hepatology; 2013 Mar; 57(3):890-6. PubMed ID: 22473858
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antiviral combination therapy with peginterferon and ribavirin does not induce a therapeutically resistant mutation in the HCV core region regardless of genetic polymorphism near the IL28B gene.
    Toyoda H; Kumada T; Hayashi K; Honda T; Katano Y; Goto H; Kawaguchi T; Murakami Y; Matsuda F
    J Med Virol; 2011 Sep; 83(9):1559-64. PubMed ID: 21739446
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin.
    Akuta N; Suzuki F; Hirakawa M; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Chayama K; Nakamura Y; Kumada H
    Hepatology; 2010 Aug; 52(2):421-9. PubMed ID: 20648473
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Association of interleukin 28B polymorphisms with response to pegylatedinterferon plus ribavirin therapy for chronic hepatitis C].
    Xu H; Guo LL; He LL; Chen Y; Liu K; Lei BJ; Lei XZ
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2012 Nov; 43(6):855-9. PubMed ID: 23387213
    [TBL] [Abstract][Full Text] [Related]  

  • 38. IL28B genomic-based treatment paradigms for patients with chronic hepatitis C infection: the future of personalized HCV therapies.
    Clark PJ; Thompson AJ; McHutchison JG
    Am J Gastroenterol; 2011 Jan; 106(1):38-45. PubMed ID: 20924369
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Significance of liver stiffness measurement by acoustic radiation force impulse (ARFI) among hepatitis C patients.
    Yamada R; Hiramatsu N; Oze T; Morishita N; Harada N; Miyazaki M; Yakushijin T; Miyagi T; Yoshida Y; Tatsumi T; Kanto T; Hayashi N; Takehara T
    J Med Virol; 2014 Feb; 86(2):241-7. PubMed ID: 24338811
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Variation in IFNL4 genotype and response to interferon-based therapy of hepatitis C in HIV-positive patients with acute and chronic hepatitis C.
    Krämer B; Nischalke HD; Boesecke C; Ingiliz P; Voigt E; Mauss S; Stellbrink HJ; Baumgarten A; Rockstroh JK; Spengler U; Nattermann J
    AIDS; 2013 Nov; 27(17):2817-9. PubMed ID: 23939236
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.